IBD biosimilar gets PBS listing

Inflectra has become the first of the so-called “mAb” biosimilars to be added to the Pharmaceutical Benefits Scheme, its maker Pfizer has announced.

The infliximab biosimilar is approved for the treatment of both adult and paediatric Crohn’s disease and ulcerative colitis, as well as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

The listing follows a PBAC